This multicenter UK RCT compared zoledronic acid (IV) versus clodronic acid (oral) as first-line bisphosphonate therapy in 1,960 patients with newly diagnosed multiple myeloma. The primary question: does the choice of bisphosphonate affect survival, not just skeletal events? Patients received concurrent intensive or non-intensive induction chemotherapy and were followed for a median of 3.7 years.
When you see a newly diagnosed myeloma patient in clinic, the bisphosphonate choice is not interchangeable. This trial established that zoledronic acid outperforms clodronic acid on overall survival (16% mortality reduction, 5.5-month extension), and that this benefit is independent of skeletal event prevention — meaning the drug is doing something beyond protecting bone.
The tradeoff is real: a 4% rate of osteonecrosis of the jaw with zoledronic acid versus under 1% with clodronic acid. Every patient starting zoledronic acid needs a pre-treatment dental evaluation, and you should counsel them specifically to avoid invasive dental procedures during therapy.
For the boards, know that the survival advantage of zoledronic acid over clodronic acid is attributed to its nitrogen-containing structure, which enables protein prenylation inhibition — a mechanism clodronic acid lacks. This is why not all bisphosphonates are equivalent in myeloma.
Also note: this trial does not support bisphosphonate use in smouldering myeloma. The benefit applies to symptomatic, newly diagnosed disease.
This multicenter UK RCT compared zoledronic acid (IV) versus clodronic acid (oral) as first-line bisphosphonate therapy in 1,960 patients with newly diagnosed multiple myeloma. The primary question: does the choice of bisphosphonate affect survival, not just skeletal events? Patients received concurrent intensive or non-intensive induction chemotherapy and were followed for a median of 3.7 years.
When you see a newly diagnosed myeloma patient in clinic, the bisphosphonate choice is not interchangeable. This trial established that zoledronic acid outperforms clodronic acid on overall survival (16% mortality reduction, 5.5-month extension), and that this benefit is independent of skeletal event prevention — meaning the drug is doing something beyond protecting bone.
The tradeoff is real: a 4% rate of osteonecrosis of the jaw with zoledronic acid versus under 1% with clodronic acid. Every patient starting zoledronic acid needs a pre-treatment dental evaluation, and you should counsel them specifically to avoid invasive dental procedures during therapy.
For the boards, know that the survival advantage of zoledronic acid over clodronic acid is attributed to its nitrogen-containing structure, which enables protein prenylation inhibition — a mechanism clodronic acid lacks. This is why not all bisphosphonates are equivalent in myeloma.
Also note: this trial does not support bisphosphonate use in smouldering myeloma. The benefit applies to symptomatic, newly diagnosed disease.